ARTICLE | Company News
Dyax licenses angiogenesis target
November 27, 2001 8:00 AM UTC
DYAX received exclusive rights from Licentia (Helsinki, Finland) to an undisclosed angiogenesis target, for use in developing antibodies and diagnostics. Also, DYAX and the University of Helsinki will...